Navigation Links
Australian Snake Venom Can Arrest Bleeding During Surgery And Trauma

It has been found that the venom of Australian snakes can rapidly arrest bleeding during major trauma and vascular surgery.The finding could eventually pave way for // development of the next generation of therapeutic drugs for humans.

Taipan venom has been found to contain high amounts of a blood-clotting protein, referred to as factor X. The gene responsible for the production of factor X has been identified by Liam St Pierre, a researcher from Queensland University of Technology.

The main focus of the study was in deciphering the genetic constitution of Taipan's venom. Liam was involved in the analysis of venom of 8 of Australia's deadliest land snakes (tiger snake, Stephens banded snake, the rough-scaled snake, the mulga, the red bellied black, the common brown and coastal Taipan) regarding their use in therapeutics. Eventually, he landed up identifying genetic code responsible for production of pro-coagulant, Factor X.

'Australian snakes literally have a two-pronged attack when they bite their prey. Firstly, venom injection causes massive blood clots instantaneously followed by paralysis as a result of neurotoxins which eventually immobilize and kill the victim,' said Dr St Pierre.

Snakes over the years have developed the ability to produce a faster acting and stable form of Factor X in their venom. This is the only alternative source for generation of Factor X, excluding the mammalian livers. The mass delivery of Factor X results in inactivation of specific human systems, resulting in death. QrxPharma, a pharmaceutical company is currently considering the initiation of clinical trials of the potential 'life-saving drug'.

The study is the first extensive study conducted on genes responsible for production of snake's toxins. Factor X has the potential to be exploited in a number of novel drug therapies. Further analysis of the different kinds of snake venom could provide for new components that could b e used for human drug development.


'"/>




Related medicine news :

1. Australian Scientists Silence Cancer Gene
2. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Australian Health funds stand accused
5. Australian Court Finds Man Guilty of Spreading HIV/AIDS
6. Australian Scientists Develop Novel Drug To Combat Inflammatory Diseases
7. Sale Of Bird Flu Vaccine to US Planned: Australian Firm
8. Hepatitis C Could Infect 800,000 Australians By 2020
9. Obesity Cost More Than The Australian Health Budget
10. Fat Virus, Ad-36 Blamed For Obesity Epidemic In Australians
11. Its High Time the Australian Government Takes Steps against Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... TX (PRWEB) , ... May 06, 2016 , ... ... of Bluvault's Integration Service, their latest implementation service offering for global clients of ... ( Appterra ). , Bluvault’s Integration Service is a key component in ...
(Date:5/6/2016)... IL (PRWEB) , ... May 06, 2016 , ... From ... in Chicago, IL, offering EarQ members the unique opportunity to learn more about Signia’s ... for independent practice growth. , “It is our priority to see practices succeed in ...
(Date:5/6/2016)... San Diego, CA (PRWEB) , ... May 06, 2016 , ... ... of Companies, has been family-owned and operated for over 35 years. Maintaining core values ... community has driven their success and made them a leading name in San Diego ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, ... Cardiovascular Institute of the South announced today that Dr. Robert Menuet, Interventional Cardiologist ... an Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... in the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 ... assessed organizations that specialize in consulting services for electronic health record (EHR) solutions ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- , First quarter 2016 adjusted diluted ... million , First quarter reported diluted (GAAP) ... , Company revises 2016 financial guidance; now expects 2016 ... 2016 adjusted diluted non-GAAP earnings per share to range from ... regarding Generics business and manufacturing facility restructuring , ...
(Date:5/5/2016)... , May 5, 2016 Research and ... Imaging in Top 5 EU Markets"  report to their offering.  ... report provides information on the current Positron Emission Tomography (PET) ... Markets (T5 EU), which includes France , ... Spain and the United ...
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
Breaking Medicine Technology: